CS Cancer Solutions - Structured Oncology Intelligence
Austria flag

Austria Cancer Research

Advanced Cancer Research with World-Class Medical Institutions in Vienna

Leading

European Cancer Centers

Vienna medical excellence

Advanced

Immunotherapy Programs

Molecular oncology research

Regional

German-Speaking Networks

International collaboration

Major Research Breakthroughs

Advanced Immunotherapy Research at Medical University of Vienna

2023-2024

Austria's premier medical center is advancing checkpoint inhibitor combinations and novel immunotherapy approaches for solid tumors.

Medical University of Vienna

Impact:

Contributing to European immunotherapy trials and biomarker research

Precision Oncology and Molecular Profiling

2024

Austrian researchers have established comprehensive molecular profiling programs for colorectal and head/neck cancers with German-speaking network collaboration.

Comprehensive Cancer Center Vienna

Impact:

Enhancing precision medicine access across Central Europe

Proton Therapy Research and Development

2022-2024

Austria is expanding proton therapy capabilities and conducting research on advanced radiation techniques for pediatric and adult cancers.

MedAustron Ion Therapy Center

Impact:

Leading particle therapy research in Central Europe

European Clinical Trial Network Participation

Ongoing

Austrian cancer centers are key participants in major European cooperative group trials, offering patients access to cutting-edge experimental therapies.

Multiple Austrian cancer centers

Impact:

Bringing international innovations to Austrian patients

Cancer Genomics and Biomarker Discovery

2023

Austria is advancing cancer genomics research with focus on identifying novel biomarkers for treatment selection and prognosis.

St. Anna Children's Cancer Research Institute

Impact:

Improving pediatric and adult cancer diagnostics

Leading Research Institutions

Medical University of Vienna

Vienna

Austria's leading medical research institution. Comprehensive oncology programs, immunotherapy research, and participation in major European trials.

Key Specialties:

Immunotherapy
Precision Oncology
Clinical Trials
Molecular Diagnostics

Comprehensive Cancer Center Vienna (CCC)

Vienna

Major cancer center offering advanced treatments and research programs. Strong collaboration with German-speaking research networks.

Key Specialties:

Molecular Profiling
GI Cancers
Head & Neck Cancers
Hematologic Malignancies

MedAustron Ion Therapy Center

Wiener Neustadt

Advanced particle therapy center conducting research on proton and ion beam therapy for complex cancers.

Key Specialties:

Proton Therapy
Particle Therapy
Pediatric Cancers
Radiation Research
Active Clinical Trials in Austria

Austria participates in major European oncology trials with advanced infrastructure

Immunotherapy Combination Study for Advanced Colorectal Cancer

Phase 2

European multi-center trial testing novel immunotherapy combinations in microsatellite-stable colorectal cancer.

Medical University of Vienna
Active recruitment

Advanced Head and Neck Cancer Precision Medicine Trial

Phase 3

Molecular profiling-guided treatment selection study for locally advanced head and neck cancers.

Comprehensive Cancer Center Vienna
Active recruitment

Proton Therapy Registry for Pediatric Cancers

Observational

Registry study collecting outcomes data on proton therapy for pediatric solid tumors.

MedAustron Ion Therapy Center
Ongoing enrollment

Want to learn about more clinical trials in Austria? Search our database.

Clinical Trials in Austria

Registry-listed trials for Austria currently tracked in our database, sourced from public trial registries.

A Randomized, 2-Arm Study to Evaluate the Efficacy and Safety of CRB-701 Compared With Investigator's Choice of Capecitabine, Cetuximab, or Docetaxel in Participants With Recurrent or Metastatic Oropharyngeal Squamous Cell Carcinoma Previously Treated With Platinum-based Chemotherapy and a PD-(L)1 Inhibitor

Phase III
Not yet recruiting
NCT07768189
View registry record

A Randomized, 2-Arm Study to Evaluate the Efficacy and Safety of CRB-701 Compared With Investigator's Choice of Capecitabine, Cetuximab, or Docetaxel in Participants With Recurrent or Metastatic Oropharyngeal Squamous Cell Carcinoma Previously Treated With Platinum-based Chemotherapy and a PD-(L)1 Inhibitor

Phase III
Not yet recruiting
NCT07768189
View registry record

A Randomized, 2-Arm Study to Evaluate the Efficacy and Safety of CRB-701 Compared With Investigator's Choice of Capecitabine, Cetuximab, or Docetaxel in Participants With Recurrent or Metastatic Oropharyngeal Squamous Cell Carcinoma Previously Treated With Platinum-based Chemotherapy and a PD-(L)1 Inhibitor

Phase III
Not yet recruiting
NCT07768189
Oropharyngeal Carcinoma (OPC)
View registry record

The MAVRiC Study: A Phase II Study of Disease Risk Mutation Guided Finite Duration Acalabrutinib Plus Venetoclax for Relapse in CLL/SLL After First-line Finite Covalent BTKi Plus BCL2i Combination, With or Without Obinutuzumab

Phase II
Recruiting
NCT07024706
Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)
View registry record

RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma

Phase III
Recruiting
NCT07491445
Pancreatic Cancer
Pancreatic Cancer Metastatic
PDAC
PDAC - Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma (PDAC)
View registry record

Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-20020 With BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase IV
Recruiting
NCT07218341
Chronic Lymphocytic Leukemia
Lymphoma, Small Lymphocytic
View registry record

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in First-Line Claudin18.2-Positive, HER2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

Phase III
Recruiting
NCT07431281
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Cancer
View registry record

A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (OPERA-02)

Phase III
Recruiting
NCT07085767
Breast Cancer
Locally Advanced Breast Cancer
Metastatic Breast Cancer
ER Positive Breast Cancer
HER2 Negative Breast Carcinoma
View registry record

- IKF/AIO-QUINTIS - A Randomized Phase II Trial Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

Phase II
Recruiting
NCT06856837
Metastatic Colorectal Cancer
View registry record

- IKF/AIO-QUINTIS - A Randomized Phase II Trial Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

Phase II
Recruiting
NCT06856837
View registry record

ImmunoMRI for Assessment of Tumor-associated Macrophages: A Prospective Study in Patients With Diffuse Large B-cell Lymphoma Receiving CAR T-cell or Bispecific Antibody Therapy

Phase I
Not yet recruiting
NCT07066436
View registry record

ImmunoMRI for Assessment of Tumor-associated Macrophages: A Prospective Study in Patients With Diffuse Large B-cell Lymphoma Receiving CAR T-cell or Bispecific Antibody Therapy

Phase I
Not yet recruiting
NCT07066436
View registry record

Latest Research Ecosystem Developments

Austria — Austria is significantly strengthening its oncology research ecosystem through strategic cross-border collaborations, increased clinical research funding, and new industry-academic partnerships focused on precision medicine.

Updated October 11, 2026

Austrian Comprehensive Cancer Network (ACCN) and Bavarian Centre for Cancer Research Cooperation

In July 2025, the ACCN and the Bavarian Centre for Cancer Research launched a strategic partnership aligned with the EU Mission Cancer to advance precision medicine, early-stage clinical trials, and joint tumor boards.

Medical University of Graz

New Christian Doppler Laboratory for Lung Cancer Research

In March 2026, the Medical University of Graz and Boehringer Ingelheim opened a new laboratory focused on non-small cell lung cancer, specifically investigating methods to trigger immunogenic cell death.

Medical University of Graz

Launch of Three New Clinical Research Groups

In July 2025, the Ludwig Boltzmann Society awarded 24 million euros to three new clinical research groups, including projects focused on bowel and bladder cancer, to bridge the gap between basic research and clinical application.

Medical University of Vienna

CCC Vienna Cancer Grants 2026

The Medical University of Vienna announced its 2026 call for the 'Initiative Krebsforschung,' providing start-up funding of up to 60,000 euros per project to support early-career researchers in translational oncology.

Comprehensive Cancer Center Vienna

EU Country Cancer Profile 2025

The 2025 EU profile highlights Austria's ongoing efforts to develop comprehensive national cancer networks to improve clinical study recruitment and the implementation of precision medicine nationwide.

OECD

This section is refreshed on a recurring schedule. Entries are AI-assisted research signals organized from public oncology sources and should be verified against the original sources. Information is educational and does not constitute medical advice.

Huippu Prodigy Platforms

© 2026 Huippu Prodigy Platforms, LLC.

CS Cancer Solutions is operated by Huippu Prodigy Platforms, LLC.

Public-Source Oncology Research • Educational and Research Use

Structured Oncology Research Intelligence